OSI Pharmaceuticals
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From OSI Pharmaceuticals
Beyond The Pandemic, An Interview With Astellas’ Percival Barretto-Ko
Astellas Pharma US accounts for roughly one-third of the parent company’s annual revenues with a growing focus on immuno-oncology. The unit’s president discusses lessons from the pandemic, racial disparities in health care and business development.
GI Endoscopy: Thriving on Innovation
Growth in the gastrointestinal endoscopy products market is being driven by advancements in GI diagnostics and screening technologies and growing adoption of high definition cameras and other enhanced imaging tools designed to improve diagnostic sensitivity and specificity in vivo, decrease the number of unnecessary procedures, and improve patient outcomes. Looking to the future, technological innovation will continue to impact growth in this market as emerging minimally invasive devices help redefine the diagnosis and treatment of GI disorders.
Recent Dealmaking (9/2003)
Summarizing the month in European dealmaking.
Company Information
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice